Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Cytovia Raises $45 Million for JV to Develop NK Products in China

publication date: Sep 16, 2021

Cytovia Therapeutics of Florida established a JV in Shanghai with an initial $45 million to develop its “off-the-shelf” CAR products in China. The JV, CytoLynx, will pay up to $400 million in milestones to Cytovia as it develops the parent company's products. Cytovia is developing gene-edited iNK and CAR-iNK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager antibodies. The $45 million initial funding was led by TF Capital and joined by other China venture capital firms. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here